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ABSTRACT 
Objective: Diabetes induces many complications such as cardiovascular problems, cataracts, kidney damage and polyneuropathy. Streptozotocin 
(STZ) induced diabetes is considered one of the most common animal models in rats. The present study investigated the effects of Monascus 
purpureus (MP) alone or in combination with pioglitazone on glucose level and on liver in streptozotocin (STZ) diabetic rats. 
Methods: In this study were divided into five experimental groups (normal, untreated STZ-diabetic (60 mg/kg B.W., IP), treated STZ-diabetic with 
Monascus purpureus (500 mg/kg B. W, oral), treated STZ-diabetic with pioglitazone (10 mg/kg B.W., oral) and treated STZ-diabetic with MP (250 
mg/kg B. W, oral)+pioglitazone (10 mg/kg B.W., oral)). Treatment continued for 14 d then blood sampling was done to assess blood glucose. At the 
end of the study, the animals were fasted overnight, anesthetized with sodium pentobarbital (60 mg/kg i.p.), and sacrificed to collect tissues 
samples (liver, pancreases).  
Results: Throughout the experimental period, all treatments significantly (P<.05) lowered serum glucose, triglycerides, cholesterol, c-peptide and 
IL-6. In addition, hepatic cholesterol and triglycerides levels were also lowered. Moreover, the treated diabetic rats showed higher activity of 
reduced glutathione (P<.05) in the liver compared with the diabetic control rats and inhibited diabetes induced elevation in the level of 
malondialdehyde in liver.  
Conclusion: The results of this study clearly demonstrated that MP act by many ways, including anti-hyperglycemic, antioxidant effects and 
pancreatic β-cell protection. From these points, it seems that MP may be a useful supplement to alleviate the development of diabetes and its 
complications. 
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INRODUCTION 
Diabetes mellitus (DM) is a metabolic disorder characterized by 
increased glucose level and insulin deficiency and/or defects of insulin 
action [1]. Type 1 diabetes is characterized by increased glucose level 
in the blood and it is known that the cause of Type 1 diabetes is the 
demolition of insulin-producing β-cells in the islets of Langerhans [2].  
During the pathogenesis of type 1 diabetes, excessive cytokines 
including interferone γ (IFN-γ), tumor necrosis factor-(TNF-α) and 
interleukin 1α (IL-1α) are generated as a result of infiltration of 
inflammatory immune cells [3]. These cytokines are the effector 
molecules for the initial destruction of pancreatic β-cells [3].  
Also, the impaired insulin secretion in type 1 diabetes increases 
mitochondrial reactive oxygen species (ROS), causing oxidative 
stress in all tissues [4]. The insulin secreting β-cell itself is the main 
target of oxidative stress because it contains low levels of 
antioxidative enzymes [5]. Therefore, protecting number and 
functions of pancreatic β-cells to maintain insulin secretion would 
help in adjusting blood glucose in type 1 diabetes patients [6]. 
The primary organs affected in diabetes are liver and kidney. The 
liver plays an important role in glucose and lipid homeostasis and is 
highly affected by diabetes and some of the changes associated with 
diabetic liver are decreased glycolysis, impeded glycogenesis and 
increased gluconeogenesis. The disease is also associated with 
marked increase in parameters such as cardiovascular risk factors 
comprising of hypertriglyceridemia, hypercholesterolemia and low 
level of high-density lipoprotein-cholesterol [7]. 
Most antidiabetic drugs enhance insulin secretion and decrease 
insulin resistance to regulate glucose homeostasis throughout the 
body and many studies have been conducted to find natural 
products for treating diabetic patients [6]. WHO reports that 90% of 
the world population in rural areas depends on traditional medicine 
for their primary healthcare and almost 70% of diabetic patients use 
plants, as a source of medicine, for their primary health needs [8]. 
From this point, we aim here to investigate one of the natural 
products that are suggested to have beneficial effects for diabetic 
patients. 
Pioglitazone belongs to the Thiazolidinedione (TZD) class of 
antidiabetic insulin sensitizers. It is used to manage obesity induced 
insulin resistance [9]. Pioglitazone, a thiazolidinedione insulin 
sensitizer, is a peroxisome proliferator activated receptor gamma 
(PPAR-γ) agonist. It increases the sensitivity of insulin by regulating 
the expression of a variety of genes involved in carbohydrate and lipid 
metabolism. Pioglitazone increases GLUT-4 and glucokinase activity 
and decreases the production of several mediators that may cause 
insulin resistance, such as tumor necrosis factor-α (TNF-α) [10].  
Pioglitazone increases hepatic and peripheral insulin sensitivity, thereby 
inhibiting gluconeogenesis and increasing peripheral and splanchnic 
glucose uptake [11]. Pioglitazone, despite significant weight gain, 
completely prevents the development of diabetes and enhances β cell 
function with preservation of islet cell changes in rats [12]. 
Monascus purpureus (MP) is a red mold which may be cultivated on 
starch containing substrates [13]. Red yeast rice obtained with 
Monascus fungus was used in China and mentioned in an ancient 
Chinese pharmacopoeia of medicinal foods and herbs. 
Manufacturing procedures of red rice were described in addition to 
the therapeutic activities, including the bettering of digestion and 
revitalizing the blood [14].  
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The traditional indications are diarrhea and intestinal troubles, 
muscular contusions and circulatory diseases. Recently, it has been 
discovered that the MP (red yeast rice) contains substances that 
resemble prescription medications that lower cholesterol, such as a 
group of monakolin K [15]. MP plays an important role in the 
management of dyslipidemia, coronary heart disease, diabetes, and 
osteoporosis [16]. However, the protective effect of MP as a 
hepatoprotective in diabetic rats has not been elucidated. Therefore, 
in the present study, we aimed to investigate the effects of MP on the 
hepatic injury induced by STZ in diabetic rats. 
MATERIALS AND METHODS  
Chemicals 
STZ was obtained from Sigma chemicals (USA). Pioglitazone was 
obtained from Takeda Pharmaceutical Company, Osaka, Japan. All 
other chemicals (acids, bases, solvents and salts) used were of 
analytical grade obtained from Sigma (USA), Monascus purpureus 
was obtained from Atos company.  
Animals 
Male albino rat (Wistar strain 150-200 g) was used for the 
experiment. Animals were obtained from the animal house colony of 
the National Research Center and housed under standard conditions 
of temperature (25±1 °C), relative humidity (55±10%), 12 hr/12 
hour light/dark cycles and fed on standard pellet diet and water ad 
libitum. The experimental protocol was approved by the 
Institutional Animal Ethical Committee of the National research 
Centre (registration number: 13/165). 
Kits 
Glucose, cholesterol, triglycerides and kits (Biodiagnostic, Egypt), 
Insulin enzyme immunoassay kit (ALPCO Insulin (Rat) ELISA kit), C-
peptide kis (RayBiotech, Inc.), Interleukin-6 (Immuno-Biological 
Laboratories, Inc. (IBL-America) were purchased. 
Methods 
Induction of diabetes 
After 1 w of acclimatization, diabetes was induced in the adult 
male Wister albino rats by using the single intraperitoneal injection 
of streptozotocin (60 mg/kg body weight). Volume of (STZ) 1 ml/kg 
body weight prepared by STZ dissolved in freshly prepared 0.01 M 
citrate buffer (pH = 4.5) [17]. On the third day of STZ injection, blood 
glucose level of rats was estimated. Rats with a blood glucose level of 
180 mg/dL beyond were considered as diabetic and included in the 
study. 
Experimental design and schedule 
Diabetic rats were randomly divided into 5 groups and each group 
contains 6 animals. Group I (Normal): untreated group. Group II 
(Diabetic Control): untreated group. Group III: treated with 
pioglitazone (10 mg/kg, oral). Group IV: treated with MP (500 
mg/kg, oral). Group V: treated with MP (250 mg/kg, 
oral)+pioglitazone (10 mg/kg, oral). Treatment was continued for 
14 d then blood sampling was done to assess blood glucose.  
Estimation of biochemical parameter 
At the end of 4-week treatment, the animals were kept for an 
overnight fasting and the blood samples were collected from retro-
orbital plexus and allowed to clot for 30 min at room temperature. 
These blood samples were centrifuged at 5000 rpm for 20 min and 
serum was separated and stored at -80 °C until analysis was done. 
Serum samples were analyzed spectrometrically for serum glucose; 
triglyceride and total cholesterol using their respective kits (Band a 
UV-visible spectrophotometer (Shimadzu UV-1601, Japan). The rats 
were then sacrificed by cervical dislocation and the liver and 
pancreas were harvested. Each liver was divided into two parts the 
first was homogenized and the other part of the liver together with 
the pancreas were fixed with 10% for histopathological, 
morphometrical and cytometrical examination. 
 
Fig. 1: Effect of Pio, MP and Pio+MP on the serum levels of 
glucose in STZ-treated diabetic rats. STZ: streptozocin Pio: 
pioglitazone, MP: Monascus purpureus. [mean±SEM, n= 6] 
significant, * when compared to normal and @ P<0.05 when 
compared to control diabetic 
 
Measurement of blood glucose levels 
Serum glucose was estimated by glucose oxidase peroxidase 
method. Serum glucose was estimated by glucose oxidase 
peroxidase method test agent kit (Stanbio, USA) according to the 
method of Trinder (1969) [18]. The absorbance was measured at 
510 nm and the results were expressed as mg/dl.  
Biochemical analysis 
Total cholesterol (TC) and Triglyceride (TG) were estimated by 
enzymatic methods. Triglycerides were estimated by enzymatic 
methods by using diagnostic kit (Biodiagnostic, Egypt) according to 
the method of Fossati and Prencipe (1982) [19]. The absorbance 
was measured at 510 nm and the results were expressed as mg/dl. 
Total cholesterol was estimated by enzymatic methods by using 
diagnostic kit (Biodiagnostic, Egypt) according to the method of 
Allain et al. (1974) [20]. The absorbance was measured at 500 nm 
and the results were expressed as mg/dl. 
Serum insulin, C-peptide and interleukin-6 
Serum insulin was estimated by a radioimmunoassay technique using 
the ALPCO Insulin (Rat) ELISA kit. Serum insulin was estimated by a 
radioimmunoassay technique using the ALPCO Insulin (Rat) ELISA kit 
according to the method of Judzewitsch et al. (1982) [21]. Serum C-
peptide was measured with a rat insulin enzyme-linked immune 
absorbent assay kit (C-Peptide EIA Kit, Sigma-Aldrich, St. Louis, MO, 
USA) [22]. Liver interleukin-6 (IL-6) was estimated using ELISA 
system (Peprotech, Rocky Hill, NJ, USA) [22].  
Measurement of antioxidant defense  
Estimation of liver lipid peroxides as thiobarbituric acid-reactive 
substances was adopted from Mihara and Uchiyama (1978) [23]. The 
resulting pink colored chromogen was extracted with butanol and was 
measured at 532 nm. Estimation of liver reduced glutathione (GSH) 
was adopted from Beutler et al., (1963) [24]. The method depends on 
the fact that both protein and non-protein thiol (SH-) groups (mainly 
GSH) react with Ellman’s reagent [5,5’-dithiobis (2-nitrobenzoic acid)] 
to form a stable yellow color of 5-mercapto-2-nitrobenzoic acid, which 
can be measured colorimetrically at 412 nm.  
Histopathology, morphometry and DNA cytometry 
For histopathology, morphometry and DNA cytometry the liver and 
pancreatic tissues were immediately transferred to 10 % formal 
saline for fixation. Paraffin embedded tissues were sectioned and 
stained with Hematoxylin and Eosin (H and E) and Feulgen stains. 
The Feulgen staining specifically stains the nuclear DNA. Nucleoli 
and cytoplasm should show no staining. The stained DNA 
quantitated and analyzed at the Pathology Department, National 
Research Center using the Leica Qwin 500 Image Analyzer (LEICA 
Imaging Systems Ltd, Cambridge, England) [25]. 
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Statistical analysis 
All the results were expressed as mean±S. E. Data was statistically 
evaluated with Graphpad prism software. Hypothesis testing 
methods included one way analysis of variance (ANOVA) followed 
by Tukey post hoc test, P<0.05 was considered to indicate 
statistical significance.  
RESULTS 
Effect of pioglitazone, Monascus purpureus (MP) and their 
combination on the serum glucose level 
STZ-induced diabetic rats have significant increase of blood glucose 
levels as compared to normal group, which further increased during 
the experimental period by 4.3 folds. Treatment of STZ-induced 
diabetic rats with pioglitazone (Pio) (10 mg/kg) produced 
significant (P<0.05) decrease in elevated serum glucose levels by 
48% as compared to the diabetic control group. Similar treatment 
with Monascus purpureus (MP) (500 mg/kg) or Pio (10 mg/kg) in 
combination with MP (250 mg/kg) produced significant (P<0.05) 
decrease in elevated serum glucose levels by 40.7% and 45.4% 
respectively as compared to the control diabetic group (fig. 1).  
Effect of pioglitazone, Monascus purpureus (MP) and their 
combination on serum and liver TG and TC levels 
STZ-induced diabetic rats were found to have significantly (P<0.05) 
elevated serum TG and TC levels by 1.7 and 3.1 folds as compared to 
the normal control group. Treatment with Pio (10 mg/kg) produced 
significant (P<0.05) decrease in elevated serum TG and TC levels by 
27% and 51% as compared to the diabetic control group. Treatment 
with MP (500 mg/kg) or Pio (10 mg/kg) in combination with MP 
(250 mg/kg) produced significant (P<0.05) decrease in elevated 
serum triglyceride level by 26.4% and 28% respectively.  
Similar treatment with MP (500 mg/kg) or Pio (10 mg/kg) in 
combination with MP (250 mg/kg) produced significant (P<0.05) 
decrease in elevated serum cholesterol by 68% and 62% 
respectively as compared to the control diabetic group (fig. 2, 3). 
On the other hands, STZ-induced diabetic rats were found to have 
significantly (P<0.05) elevated liver TG and TC levels by 1.7 and 1.78 
folds as compared to the normal control group. Treatment with Pio 
(10 mg/kg) produced significant (P<0.05) decrease in elevated liver 
TG and TC levels by 29% and 39% as compared to the diabetic 
control group. Treatment with MP (500 mg/kg) or Pio (10 mg/kg) in 
combination with MP (250 mg/kg) produced significant (P<0.05) 
decrease in elevated liver triglyceride level by 26% and 39% 
respectively. Similar treatment with MP (500 mg/kg) or Pio (10 
mg/kg) in combination with MP (250 mg/kg) produced significant 
(P<0.05) decrease in elevated liver cholesterol by 34% and 40% 
respectively as compared to the control diabetic group (fig. 4, 5). 
 
 
Fig. 2: Effect of Pio, MP and Pio+MP on the serum triglycerides 
in STZ-treated diabetic rats. STZ: streptozocin Pio: pioglitazone, 
MP: Monascus purpureus. [mean±SEM, n= 6] significant, * when 
compared to normal and @ P<0.05 when compared to control 
diabetic 
Effect of pioglitazone, Monascus purpureus (MP) and their 
combination on serum insulin level 
STZ-induced diabetic rats showed a significant decrease in 
serum insulin level by 88% as compared to normal control 
group. Treatment of STZ-induced diabetic rats with Pio (10 
mg/kg) produced significant (P<0.05) increase in reduced serum 
insulin levels by 150% as compared to the control diabetic 
group. Treatment with MP (500 mg/kg) or Pio (10 mg/kg) in 
combination with MP (250 mg/kg) produced significant (P<0.05) 
increase in reduced serum insulin levels by 200% and 350%, 
respectively (fig. 6). 
 
 
Fig. 3: Effect of Pio, MP and Pio+MP on the serum cholesterol in 
STZ-treated diabetic rats. STZ: streptozocin Pio: pioglitazone, 
MP: Monascus purpureus. [mean±SEM, n= 6] significant, * when 
compared to normal and @ P<0.05 when compared to control 
diabetic 
 
Effect of pioglitazone, Monascus purpureus (MP) and their 
combination on liver interleukin-6 (Il-6) 
STZ-induced diabetic rats showed a significant increase in liver 
Il-6 level by 5.8 folds as compared to normal control group. 
Treatment of STZ-induced diabetic rats with Pio (10 mg/kg) 
produced significant (P<0.05) increase in reduced liver Il-6 
levels by 62% as compared to the control diabetic group. 
Treatment with MP (500 mg/kg) or Pio (10 mg/kg) in 
combination with MP (250 mg/kg) produced significant (P<0.05) 
decrease in elevated liver insulin levels by 35% and 78%, 
respectively (fig. 7). 
 
 
Fig. 4: Effect of Pio, MP and Pio+MP on the liver triglycerides in 
STZ-treated diabetic rats. STZ: streptozocin Pio: pioglitazone, 
MP: Monascus purpureus. [mean±SEM, n= 6] significant, * when 
compared to normal and @ P<0.05 when compared to control 
diabetic 
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Fig. 5: Effect of Pio, MP and Pio+MP on the liver cholesterol in 
STZ-treated diabetic rats. STZ: streptozocin Pio: pioglitazone, 
MP: Monascus purpureus. [mean±SEM, n= 6] significant, * when 




Fig. 6: Effect of Pio, MP and Pio+MP on the serum insulin in STZ-
treated diabetic rats. STZ: streptozocin Pio: pioglitazone, MP: 
Monascus purpureus. [mean±SEM, n= 6] significant, * when 




Fig. 7: Effect of Pio, MP and Pio+MP on serum IL-6 in STZ-treated 
diabetic rats. STZ: streptozocin Pio: pioglitazone, MP: Monascus 
purpureus. [mean±SEM, n= 6] significant, * when compared to 
normal and @ P<0.05 when compared to control diabetic 
 
STZ-induced diabetic rats showed a significant decrease in the 
serum GSH by 49% as compared to normal control group. Treatment 
of STZ-induced diabetic rats with Pio (10 mg/kg) produced 
significant (P<0.05) increase in the serum GSH level 31% as 
compared to the control diabetic group. Treatment with MP (500 
mg/kg) or Pio (10 mg/kg) in combination with MP (250 mg/kg) 
produced significant (P<0.05) increase in the serum GSH level by 
70% and 119%, respectively (fig. 8).  
However, STZ-induced diabetic rats showed a significant increase in 
the serum MDA by 153% as compared to normal control group. 
Treatment of STZ-induced diabetic rats with Pio (10 mg/kg) 
produced significant (P<0.05) decrease in the serum MDA level by 
42% as compared to the control diabetic group. Treatment with MP 
(500 mg/kg) or Pio (10 mg/kg) in combination with MP (250 
mg/kg) produced significant (P<0.05) decrease in the serum MDA 
level by 30% and 46.5%, respectively (fig. 9).  
Effect of pioglitazone, Monascus purpureus (MP) and their 
combination on hepatic and pancreatic histology 
Gross examination of liver showed no abnormalities. The 
microscopic examination of sections of liver from control group 
showed preserved hepatic architecture with normal hepatocytes. 
Sections of liver tissue of STZ-treated rats showed normal hepatic 
architecture with focal inflammatory cellular infiltrate and focal 
hepatocytic degeneration. Sections of liver treated with Pio (10 
mg/kg) showed moderate degeneration of hepatocytes with mild 
cellular infiltrate. Sections of liver tissue treated with MP (500 
mg/kg) treated rats showed moderate hepatic infiltration by 
inflammatory cells. Liver tissue of the group treated with Pio (10 
mg/kg) in combination with MP (250 mg/kg) showed mild focal 
degeneration of hepatocytes.  
 
 
Fig. 8: Effect of Pio, MP and Pio+MP on liver GSH in STZ-treated 
diabetic rats. STZ: streptozocin Pio: pioglitazone, MP: Monascus 
purpureus. [mean±SEM, n= 6] significant, * when compared to 
normal and @ P<0.05 when compared to control diabetic 
 
 
Fig. 9: Effect of Pio, MP and Pio+MP on liver GSH in STZ-treated 
diabetic rats. STZ: streptozocin Pio: pioglitazone, MP: Monascus 
purpureus. [mean±SEM, n= 6] significant, * when compared to 
normal and @ P<0.05 when compared to control diabetic 
 
Effect of pioglitazone, Monascus purpureus (MP) and their 
combination on morphometric parameters 
The morphometric examination of the normal pancreatic tissue 
sections showed that the islets are of normal size and have intact Beta 
cells. STZ-treated pancreatic specimens showed shrunk islets with 
degenerated Beta cells and peripheral lymphocytic infiltrate. Sections 
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of pancreatic tissue treated with Pio (10 mg/kg) showed small islets 
with decreased number of Beta cells than control. Sections of 
pancreatic tissue treated with MP (500 mg/kg) showed that the islets 
had decreased number of Beta cells. Sections of pancreatic tissue 
treated with Pio (10 mg/kg) in combination with MP (250 mg/kg) 





































Fig. 10: Photomicrograph of Pio, MP and Pio+MP on liver in STZ-treated diabetic rats. STZ: streptozocin Pio: pioglitazone, MP: Monascus 
purpureus. [mean±SEM, n= 6] significant, * when compared to normal and @ P<0.05 when compared to control diabetic 
 
A-Section in control liver tissue showing preserved hepatic architecture 
with normal hepatocytes (H and E, X100). B-Section in normal 
pancreatic tissue, the islets show intact Beta cells (H and E, X100). C-
Normal pancreatic tissue section with overlapped binary image showing 
a mean islet area 1278.26 square micrometer. D-Section of liver tissue 
from STZ treated rat showing normal hepatic architecture with focal 
inflammatory cell infiltrates with focal hepatocytic degeneration (H and 
E, X100). E-STZ pancreatic tissue section, the islets show degenerated 
Beta cells with peripheral lymphocytic infiltrate (H and E, X100). F-
Pancreatic sections from STZ treated rat with overlapped binary image 
showing a mean islet area 785.42 square micrometer. J-Section of liver 
tissue from Pio treated rat showing moderate degeneration of 
hepatocytes with mild cellular infiltrate (H and E, X100). K-Pio treated 
pancreatic tissue section showed that the islets have few Beta cells (H 
and E, X100). L-Pancreatic sections from Pio treated rat with mean islet 
area 549.28 square micrometer. M-Section of liver tissue from Stat 
treated rat showing moderate hepatic infiltration by inflammatory cells 
(H and E, X100). N-Stat treated pancreatic tissue section showed that the 
islets had decreased number of Beta cells (H and E, X100). O-Pancreatic 
sections from Stat treated rat with mean islet area 724.11 square 
micrometer. P-Section of liver tissue from PS treated rat showing focal 
degeneration of hepatocytes (H and E, X100). Q-PS treated pancreatic 
tissue section; the islets show decreased number of Beta cells with 
peripheral inflammatory cellular infiltrate (H and E, X100). R-
Pancreatic sections from PS treated rat with mean islet area 659.89 
square micrometer. 
 
Table 1: Morphometric analysis of Pio, MP and Pio+MP on liver in STZ-treated diabetic rats 
Drugs Pancreatic islets Mean islets area Hepatocytic degeneration Inflammatory infiltrate 
N Normal islets with normal B cells 1278.26 --- --- 
STZ Atrophic islets with degenerated B cells 785.42 +++ +++ 
Pio Few Beta cells 549.28 ++ ++ 
MP Decreased number of Beta cells  724.11 ++ ++ 
Pio+MP Decreased number of Beta cells with peripheral 
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DISCUSSION 
Streptozotocin (STZ)-induced hyperglycemia rat is a well-
established model for the first screening of antidiabetic agents [26]. 
Streptozotocin produces diabetes that is equivalent to the pathological 
status found in human diabetes [27]. In the present study, the 
intraperitoneal administration of streptozotocin induced diabetes 
mellitus in rats. STZ-induced experimental diabetes results in many 
diabetic complications that are mediated through oxidative stress [28]. 
An imbalance between the oxidant and antioxidant status occur as a 
result of the generation of reactive oxygen species [29].  
Streptozotocin is cytotoxic to pancreatic β-cells [30, 31]. The toxic 
effect of STZ involves its uptake into cells due to the glucose moiety 
in its chemical structure which causes the entrance of STZ to the β-
cell via the low affinity glucose 2 transporter in the plasma 
membrane as they are more dynamic than other cells in taking up 
glucose, and thus, more subtle than other cells to STZ contest and 
hence STZ causes direct DNA damage to the pancreatic islets of beta 
cells, which leads to hyperglycemic state [32, 33]. 
In the present study, administration of STZ resulted in a significant 
rise in the blood glucose level and lessening in plasma insulin level. 
Hyperglycemia resulted in increased levels of free radicals by 
autoxidation of glucose, protein glycation, and oxidative stress. 
Hyperglycemia is associated with the production of ROS resulting in 
oxidative damage in different body organs, mostly to the heart, 
kidney, eyes, nerves, liver and gastrointestinal system [34]. These 
changes were confirmed by the histopathological examination of the 
liver and pancreas which showed focal degenerative changes in 
hepatocytes and shrunk islets with degenerated Beta cells. 
The use of medicinal plants in the treatment of many diseases is 
increasing and it is an important part of medicinal therapy. However, 
many botanicals have been used traditionally in the treatment of 
diabetes, little definitive and clear data on the efficacy of such natural 
products has been documented and still needs research [35]. 
Oral administration of Monascus purpureus (MP) reduced the blood 
glucose level and improved plasma insulin level in diabetic rats. This 
may be due to the insulin like effect of MP on peripheral tissues, 
either by promoting glucose uptake and metabolism or by hindering 
hepatic gluconeogenesis. 
From the results of the present study, it seems that there is an 
increase in the concentration of TC and TG in STZ-induced diabetic 
rats. Hyperlipidemia is a predictable consequence of DM [36].  
DM induced hyperlipidemia is attributable to the surplus 
mobilization of fat from the adipose tissue due to the 
underutilization of the glucose [37]. The TC and TG of diabetic rats 
treated with MP were decreased as compared to diabetic control 
rats.  
Regarding the mechanism of action of MP, it may have enhanced the 
activity of enzymes involved in bile acid synthesis and its excretion 
and thus decreased serum levels of TC and TG [38]. Most of the 
hypolipidemic drugs do not decrease serum TG level, but MP 
decreased it significantly which might be attributed to the cause 
that, under the diabetic condition, insulin stimulates the enzyme 
lipoprotein lipase thus causes the hydrolysis of TG [39]. 
The present study showed a reduction in the level of insulin in 
diabetic rats, which is similar to other studies [40]. Administration 
of pioglitazone, MP or their combination to diabetic rats significantly 
increased the level of insulin which might be accredited to the 
insulin like effect of MP on peripheral tissues, either by promoting 
glucose uptake and metabolism or by inhibiting hepatic 
gluconeogenesis [41].  
STZ-induced diabetic rats showed an increase in liver IL-6 compared 
with that of the normal group. Administration of pioglitazone, MP or 
their combination to diabetic rats significantly restored the elevated 
IL-6 levels. Interleukin-6 is a cytokine involved not only in 
inflammation and infection responses but also in the regulation of 
metabolic, regenerative, and neural processes [42]. However, the 
increase of IL-6 was decreased with the concurrent treatment with 
pioglitazone, MP or their combination that suggests that MP has 
antidiabetic activity.  
Increased release of free radicals was observed in diabetic rats and 
it is accredited to the chronic hyperglycemia that damage 
antioxidant defense system [43]. Free radicals may also be formed 
through the auto-oxidation of unsaturated lipids in plasma and 
membrane lipids.  
The produced free radicals may react with polyunsaturated fatty 
acids in cell membrane leading to lipid peroxidation that will in turn 
results in raised production of free radicals [44]. Increased lipid 
peroxidation damages membrane functions by decreasing the 
membrane fluidity and altering the activity of membrane-bound 
enzymes and receptors [45].  
The present study showed a significant raise in tissue thiobarbituric 
acid reactive substances (TBARS) in diabetic rats. This increased 
TBARS content in diabetic rats echoes the peroxidative damage that 
might be involved in the progress of diabetic complications. TBARS 
levels in liver were significantly lower in the treated group compared 
to the diabetic control rats. This suggests that the MP may possess 
antioxidant activities and guard the tissues against lipid peroxidation.  
GSH is a main endogenous antioxidant which acts against free radical 
mediated damage. Earlier studies showed that the tissue GSH levels of 
STZ-induced diabetic rats are significantly minor when compared with 
the normal rats [46]. It is well known that GSH is involved in the 
protection of normal cell construction and function by preserving the 
redox homeostasis, quenching of free radicals and contributing in 
detoxification reactions as it is a direct scavenger of free radicals [47].  
It has been proposed that the decrease in tissue GSH could be the 
result of decreased synthesis or increased degradation of GSH by 
oxidative stress in diabetes [48]. In the present study, the elevation 
of GSH levels in liver was observed in the MP and pioglitazone 
treated diabetic rats. This indicates that the MP and pioglitazone can 
either increase the biosynthesis of GSH or diminish the oxidative 
stress leading to less degradation of GSH or have both effects. 
Studies revealed that free radicals are formed excessively in DM by 
glucose oxidation, non-enzymatic glycation of proteins. High levels 
of free radicals and the concurrent decline of antioxidant defense 
mechanisms may cause damage to cellular organelles and enzymes, 
thus increased lipid peroxidation [49].  
Thiobarbituric acid reactive substances (TBARS) assessment in 
plasma helps to evaluate the extent of tissue damage [50]. In the 
present study, we found an increase in the levels of serum TBARS, 
which is a key factor of lipid peroxidation. The major pathological 
outcome of membrane lipid peroxidation by free radical induction 
comprises increased membrane rigidity, decreased cellular 
deformability, reduced erythrocyte survival, and lipid fluidity [50].  
The tissue lipid peroxidation in diabetic rats was increased, which 
might be due to an increase in the level of blood glucose [51]. Lipid 
peroxidation mediated tissue damage has been detected during the 
progress of DM; this is one of the specific features of chronic DM. 
The level of lipid peroxidation was increased in the tissues of 
diabetic rats, which might be due to a significant rise in the levels of 
TBARS and hydroperoxides in the liver and kidney.  
The present data of lipid peroxidation come in accordance with the 
findings of Kakkar et al. (1997) [52]. MP, pioglitazone or their 
combination significantly decreased the elevated levels of 
malondialdehyde which is the indicator for lipid peroxidation wjich 
reflects the antidiabetic effects. 
Histologically, liver and pancreatic tissues of the groups treated with 
Pio, MP or their combination showed amelioration of the atrophic 
changes and the degenerative effect of diabetes on islets and 
hepatocytes. 
CONCLUSION 
The pathogenesis of diabetes and its diabetes complications is 
complex. MP has an antidiabetic effect in STZ-induced diabetes in 
rats. The present study shows that MP has beneficial effects, 
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counting the control of hyperglycemia, pancreatic β-cell shield and 
antioxidant effects. From this point, it seems that MP may be a 
valuable adjunct supplement to delay the progress of diabetes and 
diabetes complications. However, further studies are necessary to 
explore the underlying mechanism of treatment of MP. 
CONFLICT OF INTERESRTS 
The authors have declared that no conflict of interests exists 
REFERENCES 
1. Sellamuthu PS, Arulselvan P, Fakurazi S, Kandasamy M. Beneficial 
effects of mangiferin isolated from Salacia chinensis on 
biochemical and hematological parameters in rats with 
streptozotocin-induced diabetes. Pak J Pharm Sci 2014;27:161-7. 
2. Atkinson MA, Maclaren NK. The pathogenesis of insulin-
dependent diabetes mellitus. N Engl J Med 1994;331:1428-36. 
3. Eizirik DL, Colli ML, Ortis F. The role of inflammation in 
insulitis and beta-cell loss in type 1 diabetes. Nat Rev 
Endocrinol 2009;5:219-26. 
4. Giacco F, Brownlee M. Oxidative stress and diabetic 
complications. Circ Res 2010;107:1058-70. 
5. Kajimoto Y, Kaneto H. Role of oxidative stress in pancreatic 
beta-cell dysfunction. Ann N Y Acad Sci 2004;1011:168-76. 
6. Ghazanfar K, Ganai BA, Akbar S, Mubashir K, Dar SA, Dar MY, et al. 
Antidiabetic activity of Artemisia amygdalina decne in 
streptozotocin induced diabetic rats. Biomed Res Int 2014;18:56-6. 
7. Kannel WB. Lipids, diabetes, and coronary heart disease: insights 
from the framingham study. Am Heart J 1985;110:1100-7. 
8. Sharma BR, Rhyu DY. Anti-diabetic effects of Caulerpa 
lentillifera: stimulation of insulin secretion in pancreatic beta-
cells and enhancement of glucose uptake in adipocytes. Asian 
Pac J Trop Biomed 2014;4:575-80. 
9. Johnson DB, Gerstein DE, Evans AE, Woodward-Lopez G. 
Preventing obesity: a life cycle perspective. J Acad Nutr Diet 
2006;106:97-102. 
10. Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 
diabetes mellitus. Can Med Assoc J 2005;172:213-26. 
11. Waugh J, Keating GM, Plosker GL, Easthope S, Robinson DM. 
Pioglitazone: a review of its use in type 2 diabetes mellitus. 
Drugs 2006;66:85-109. 
12. Choi SY, Noh MR, Kim DK, Sun W, Kim H. Neuroprotective 
function of thymosin-beta and its derivative peptides on the 
programmed cell death of chick and rat neurons. Biochem 
Biophys Res Commun 2007;362:587-93. 
13. Dominguez CM. Diabetes, the americans with disabilities act, 
and the eeoc. Diabetes Forecast 2003;56:66-8. 
14. Erdogrul O, Covaci A, Kurtul N, Schepens P. Levels of 
organohalogenated persistent pollutants in human milk from 
kahramanmaras region, turkey. Environ Int 2004;30:659-66. 
15. Li YG, Zhang F, Wang ZT, Hu ZB. Identification and chemical 
profiling of monacolins in red yeast rice using high-
performance liquid chromatography with photodiode array 
detector and mass spectrometry. J Pharm Biomed Anal 
2004;35:1101-12. 
16. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fonnebo V. Chinese 
red yeast rice (Monascus purpureus) for primary 
hyperlipidemia: a meta-analysis of randomized controlled 
trials. Chin Med 2006;1:4. 
17. Brosky G, Logothetopoulos J. Streptozotocin diabetes in the 
mouse and guinea pig. Diabetes 1969;18:606-11. 
18. Trinder P. Determination of blood glucose using 4-amino 
phenazone as oxygen acceptor. J Clin Pathol 1969;22:246. 
19. Fossati P, Prencipe L. Serum triglycerides determined 
colorimetrically with an enzyme that produces hydrogen 
peroxide. Clin Chem 1982;28:2077-80. 
20. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic 
determination of total serum cholesterol. Clin Chem 
1974;20:470-5. 
21. Judzewitsch RG, Pfeifer MA, Best JD, Beard JC, Halter JB, Porte D 
Jr. Chronic chlorpropamide therapy of noninsulin-dependent 
diabetes augments basal and stimulated insulin secretion by 
increasing islet sensitivity to glucose. J Clin Endocrinol Metab 
1982;55:321-8. 
22. Shi YC, Liao JW, Pan TM. Antihypertriglyceridemic and anti-
inflammatory activities of Monascus-fermented dioscorea in 
streptozotocin-induced diabetic rats. J Diabetes Res 2011. 
Doi.org/10.1155/2011/710635. [Article in Press] 
23. Mihara M, Uchiyama M. Determination of malonaldehyde 
precursor in tissues by thiobarbituric acid test. Anal Biochem 
1978;86:271-8. 
24. Beutler E, Duron O, Kelly BM. Improved method for the 
determination of blood glutathione. J Lab Clin Med 
1963;61:882-8. 
25. Hamilton PW, Allen DC. Morphometry in histopathology. J 
Pathol 1995;175:369-79. 
26. Ivorra MD, Paya M, Villar A. A review of natural products and 
plants as potential antidiabetic drugs. J Ethnopharmacol 
1989;27:243-75. 
27. Larsen MO, Wilken M, Gotfredsen CF, Carr RD, Svendsen O, 
Rolin B. Mild streptozotocin diabetes in the gottingen minipig. 
A novel model of moderate insulin deficiency and diabetes. 
Am J Physiol Endocrinol Metab 2002;282:E1342-51. 
28. Ozturk Y, Altan VM, Yildizoglu-Ari N. Effects of experimental 
diabetes and insulin on smooth muscle functions. Pharmacol 
Rev 1996;48:69-112. 
29. Noda Y, Kneyuki T, Igarashi K, Mori A, Packer L. Antioxidant 
activity of nasunin, an anthocyanin in eggplant peels. Toxicol 
2000;148:119-23. 
30. Junod A, Lambert AE, Orci L, Pictet R, Gonet AE, Renold AE. 
Studies of the diabetogenic action of streptozotocin. Proc Soc 
Exp Biol Med 1967;126:201-5. 
31. Rerup CC. Drugs producing diabetes through damage of the 
insulin secreting cells. Pharmacol Rev 1970;22:485-518. 
32. Elsner M, Guldbakke B, Tiedge M, Munday R, Lenzen S. Relative 
importance of transport and alkylation for pancreatic beta-cell 
toxicity of streptozotocin. Diabetologia 2000;43:1528-33. 
33. Solanki ND, Bhavsar SK. An evaluation of the protective role of 
Ficus racemosa linn. in streptozotocin-induced diabetic 
neuropathy with neurodegeneration. Indian J Pharmacol 
2015;47:610-5. 
34. Tunali S, Yanardag R. Effect of vanadyl sulfate on the status of 
lipid parameters and on stomach and spleen tissues of 
streptozotocin-induced diabetic rats. Pharmacol Res 
2006;53:271-7. 
35. Soon YY, Tan BK. Evaluation of the hypoglycemic and anti-
oxidant activities of Morinda officinalis in streptozotocin-
induced diabetic rats. Singapore Med J 2002;43:77-85. 
36. Ktari N, Mnafgui K, Nasri R, Hamden K, Bkhairia I, Ben Hadj A, 
et al. Hypoglycemic and hypolipidemic effects of protein 
hydrolysates from zebra blenny (Salaria basilisca) in alloxan-
induced diabetic rats. Food Funct 2013;4:1691-9. 
37. Krishnakumar K, Augusti KT, Vijayammal PL. Anti-peroxidative 
and hypoglycaemic activity of Salacia oblonga extract in 
diabetic rats. Pharm Biol 2000;38:101-5. 
38. Sethupathy S, Elanchezhiyan C, Vasudevan K, Rajagopal G. 
Antiatherogenic effect of taurine in high fat diet fed rats. Indian 
J Exp Biol 2002;40:1169-72. 
39. Frayn KN, Coppack SW, Humphreys SM, Clark ML, Evans RD. 
Periprandial regulation of lipid metabolism in insulin-treated 
diabetes mellitus. Metab Clin Exp 1993;42:504-10. 
40. Saravanan G, Ponmurugan P. S-allylcysteine improves 
streptozotocin-induced alterations of blood glucose, liver 
cytochrome p450 2e1, plasma antioxidant system, and 
adipocytes hormones in diabetic rats. Int J Endocrinol Metab 
2013;11:e10927. Doi:10.5812/ijem.10927. [Article in Press] 
41. Patel MB, Mishra SH. Hypoglycemic activity of c-glycosyl 
flavonoid from Enicostemma hyssopifolium. Pharm Biol 
2011;49:383-91. 
42. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro-
and anti-inflammatory properties of the cytokine interleukin-6. 
Biochim Biophys Acta 2011;1813:878-88. 
43. Kumar G, Murugesan AG. Hypolipidaemic activity of Helicteres 
isora l. Bark extracts in streptozotocin induced diabetic rats. J 
Ethnopharmacol 2008;116:161-6. 
44. Menendez JA, Colomer R, Lupu R. Inhibition of fatty acid 
synthase-dependent neoplastic lipogenesis as the mechanism 
of gamma-linolenic acid-induced toxicity to tumor cells: an 
Awdan et al.  
Int J Pharm Pharm Sci, Vol 8, Issue 8, 107-114 
114 
extension to nwankwo's hypothesis. Med Hypotheses 
2005;64:337-41. 
45. Baynes JW. Role of oxidative stress in development of 
complications in diabetes. Diabetes 1991;40:405-12. 
46. Ewis SA, Abdel-Rahman MS. Effect of metformin on glutathione 
and magnesium in normal and streptozotocin-induced diabetic 
rats. J Appl Toxicol 1995;15:387-90. 
47. Winterbourn CC, Metodiewa D. Reaction of superoxide with 
glutathione and other thiols. Method Enzymol 1995;251:81-
6. 
48. Loven D, Schedl H, Wilson H, Daabees TT, Stegink LD, Diekus 
M, et al. Effect of insulin and oral glutathione on glutathione 
levels and superoxide dismutase activities in organs of rats 
with streptozocin-induced diabetes. Diabetes 1986;35:503-7. 
49. Maritim AC, Sanders RA, Watkins JB. 3rd: Diabetes, oxidative 
stress, and antioxidants: a review. J Biochem Mol Toxicol 
2003;17:24-38. 
50. Gutteridge JM. Lipid peroxidation and antioxidants as 
biomarkers of tissue damage. Clin Chem 1995;41:1819-28. 
51. Erejuwa OO, Gurtu S, Sulaiman SA, Ab Wahab MS, Sirajudeen 
KN, Salleh MS. Hypoglycemic and antioxidant effects of honey 
supplementation in streptozotocin-induced diabetic rats. Int J 
Vitam Nutr Res 2010;80:74-82. 
52. Kakkar R, Mantha SV, Radhi J, Prasad K, Kalra J. Antioxidant 
defense system in diabetic kidney: a time course study. Life Sci 
1997;60:667-79. 
How to cite this article 
• Gehad A Abdel Jaleel, Dalia O Saleh, Sally A EL Awdan, Manal 
Badawi. Hepatoprotective activity of Monascus purpureus (Red 
Rice Yeast) in diabetic rats alone or in combination with 
piogliazone: An effect mediated through cytokines, antioxidants 
and lipid biomarkers. Int J Pharm Pharm Sci 2016;8(8):107-114.
 
